These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34617309)

  • 21. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy.
    Heberer K; Fowler E; Staudt L; Sienko S; Buckon CE; Bagley A; Sison-Williamson M; McDonald CM; Sussman MD
    Gait Posture; 2016 Jul; 48():159-164. PubMed ID: 27267770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of corticosteroids in muscular dystrophy: a critical appraisal.
    Angelini C
    Muscle Nerve; 2007 Oct; 36(4):424-35. PubMed ID: 17541998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.
    Escolar DM; Zimmerman A; Bertorini T; Clemens PR; Connolly AM; Mesa L; Gorni K; Kornberg A; Kolski H; Kuntz N; Nevo Y; Tesi-Rocha C; Nagaraju K; Rayavarapu S; Hache LP; Mayhew JE; Florence J; Hu F; Arrieta A; Henricson E; Leshner RT; Mah JK
    Neurology; 2012 Mar; 78(12):904-13. PubMed ID: 22402864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
    Angelini C; Peterle E
    Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.
    Kinali M; Mercuri E; Main M; Muntoni F; Dubowitz V
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S169-74. PubMed ID: 12206813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy.
    Buckon CE; Sienko SE; Fowler EG; Bagley AM; Staudt LA; Sison-Williamson M; Heberer KR; McDonald CM; Sussman MD
    J Neuromuscul Dis; 2022; 9(2):321-334. PubMed ID: 34924398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet.
    Butterfield RJ; Kirkov S; Conway KM; Johnson N; Matthews D; Phan H; Cai B; Paramsothy P; Thomas S; Feldkamp ML
    Muscle Nerve; 2022 Jul; 66(1):15-23. PubMed ID: 34994466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticosteroid therapy for duchenne muscular dystrophy: improvement of psychomotor function.
    Sato Y; Yamauchi A; Urano M; Kondo E; Saito K
    Pediatr Neurol; 2014 Jan; 50(1):31-7. PubMed ID: 24138948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy.
    Dubowitz V; Kinali M; Main M; Mercuri E; Muntoni F
    Eur J Paediatr Neurol; 2002; 6(3):153-9. PubMed ID: 12363102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy.
    Lamb MM; Cai B; Royer J; Pandya S; Soim A; Valdez R; DiGuiseppi C; James K; Whitehead N; Peay H; Venkatesh SY; Matthews D;
    Am J Med Genet A; 2018 Nov; 176(11):2350-2358. PubMed ID: 30256515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
    Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy.
    Silva EC; Machado DL; Resende MB; Silva RF; Zanoteli E; Reed UC
    Arq Neuropsiquiatr; 2012 Mar; 70(3):191-5. PubMed ID: 22392111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.